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https://doi.org/10.1016/j.molcel.2018.08.028SUMMARY
Antibiotic-resistant bacterial pathogens pose an ur-
gent healthcare threat, prompting a demand for
new medicines. We report the mode of action of the
natural ansamycin antibiotic kanglemycin A (KglA).
KglA binds bacterial RNA polymerase at the rifam-
picin-binding pocket but maintains potency against
RNA polymerases containing rifampicin-resistant
mutations. KglA has antibiotic activity against
rifampicin-resistant Gram-positive bacteria and
multidrug-resistant Mycobacterium tuberculosis
(MDR-M. tuberculosis). The X-ray crystal structures
of KglAwith the Escherichia coliRNA polymerase ho-
loenzyme and Thermus thermophilus RNA polymer-
ase-promoter complex reveal an altered—compared
with rifampicin—conformation of KglA within the
rifampicin-binding pocket. Unique deoxysugar and
succinate ansa bridge substituents make additional
contacts with a separate, hydrophobic pocket of
RNA polymerase and preclude the formation of initial
dinucleotides, respectively. Previous ansa-chain
modifications in the rifamycin series have proven un-
successful. Thus, KglA represents a key starting
point for the development of a new class of ansa-
chain derivatized ansamycins to tackle rifampicin
resistance.
INTRODUCTION
Antibiotic resistance is on the increase, exacerbated by the fact
that, in recent years, only a few new compounds have reachedMolecular Cell
This is an open access article under the Open Government License (OGL) (the clinic. RNA polymerase (RNAP) is an essential enzyme ac-
complishing transcription in all living organisms. At the same
time, the sequence divergence between bacterial and human
RNAPs makes bacterial RNAP an excellent target for antibiotic
development (Ho et al., 2009). In the last few years, details of
the mode of action of a number of inhibitors of RNAP have
been described (Bae et al., 2015; Degen et al., 2014; Maffioli
et al., 2017; Molodtsov et al., 2015; Mukhopadhyay et al.,
2008; Zhang et al., 2014a). However, most of these molecules
have limited clinical utility, mainly because of their poor penetra-
tion of the bacterial cell envelope or strong binding to human
plasma protein. Nevertheless, the search for new molecules
that target RNAP and analysis of their mode of action is a prom-
ising approach for the development of new antibiotics, as exem-
plified by the now clinically used fidaxomicin (trade name Dificid)
for Clostridium difficile-associated diarrhea (Tupin et al., 2010).
The most studied class of antibiotics known to inhibit bacterial
RNA transcription are the rifamycins, a family of mainly semisyn-
thetic ansamycins derived from the natural product rifamycin S,
of which rifampicin (RIF) is the most widely used (Aristoff et al.,
2010). RIF (and the other rifamycins) binds in a pocket (the RIF
pocket) on the b subunit of RNAP in the vicinity of the catalytic
site and sterically blocks propagation of the growing RNA chain
through the main channel of RNAP (Campbell et al., 2001;
McClure and Cech, 1978). The collision of RNA and RIF happens
when the RNA reaches a length of 3–4 nucleotides, after which
the RNA is released from the promoter complex as an abortive
transcript. The length of the abortive RNA product can be
influenced by the nature of the C3 substituent of the individual
semisynthetic rifamycin. For example, rifabutin even inhibits syn-
thesis of a trinucleotide (when reaction is started with a 50-non-
phosphorylated dinucleotide primer), whereas RIF still allows it
(Artsimovitch et al., 2005).
The rifamycins are used, as part of the current combination
therapy, for the first-line treatment of tuberculosis (TB), the72, 1–12, October 18, 2018 ª 2018 The Authors. Published by Elsevier Inc. 1
http://www.nationalarchives.gov.uk/doc/open-government-licence/version/3/).
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Health Organization, 2017), aswell as treatment for non-tubercu-
lous mycobacterial infections (Ryu et al., 2016). One of the major
problems with known rifamycins is the rapid selection for muta-
tions in the RIF-binding pocket of RNAP that lead to resistance.
Multidrug-resistant strains of Mycobacterium tuberculosis
(MDR-M. tuberculosis) present a major clinical problem because
these strains are resistant to RIF in addition to isoniazid. In 2016,
there were 600,000 new cases with resistance to RIF, of which
490,000 had MDR-TB. With a treatment success rate of only
54%, this highlights the requirement for improved treatment
options. There are 100 different amino acid substitutions in
the RIF pocket that have been found in RIF-resistant clinical iso-
lates ofM. tuberculosis (Sandgren et al., 2009), with mutations at
three positions of the RIF pocket that account for 70% of the
total substitutions (D516, 7.4%; H526, 20%; S531, 42%; E. coli
numbering).
Previous efforts to probe the structure-activity relationships of
the rifamycins and, thus, to maximize their binding affinity for
RNAP have shown that the minimum structural requirements
essential for activity include two free hydroxyl groups at the
C21 and C23 positions of the ansa chain and two polar (free hy-
droxyl or carbonyl) groups at the C1 and C8 positions of the nap-
thoquinone ring. Furthermore the molecule must be able to
adopt a specific conformational geometry to position these key
functional groups in the correct spatial arrangement required
for RNAP binding (Bacchi et al., 1998; Lancini and Zanichelli,
1977). Thus, modification of the ansa bridge (e.g., hydrogenation
or epoxidation of the C16,17 or C18,19 carbon-carbon double
bonds) results in decreased binding to RNAP because of confor-
mational changes in the molecule altering the spatial arrange-
ment of the C1, C8, C21, and C23 functional groups, thus
disrupting their critical hydrogen bonds with the RIF pocket
(Aristoff et al., 2010; Bacchi et al., 2008). Hence, the production
of clinically used semisynthetic rifamycins (RIF, rifabutin, rifapen-
tine, rifalazil, and rifaximin) has focused on the introduction of
functionality at the C3 position to stabilize the oxidation state
of the naphthoquinone core and to improve bioavailability (Floss
and Yu, 2005; Perlman, 1977).
Here we isolated and, by using microbiological, biochemical,
and structural biology techniques, studied an uncharacterized
naturally produced antibiotic, kanglemycin A (KglA). KglA is an
ansamycin antibiotic from the rifamycin family that displays
two important and unusual ansa bridge modifications. We
show that, despite having a mode of action similar to that ofFigure 1. Identification and Mode of Action of KglA
(A) Disk diffusion assay with rifampicin (RIF), carbenicillin (Cb), and kanglemycin A
typeB. subtilis carrying the lacZ gene under thePhelD promoter, inducible during p
blue halo around the growth inhibition zones in the case of transcription inhibitor
(B) Chemical structure of KglA in comparison with RIF. The ansa chain modificati
See also Figure S1 and Table S1.
(C) Transcription in vitro by E. coli RNAP started with CpA on a linear template c
nucleotides are marked. Note that tetra-nucleotides migrate faster than tri-nucle
(D) Different ratio of the di-nucleotide-long (pppApU) and the tri-nucleotide-long
was performed in the presence of the nucleotides depicted (in the absence of the
in the well.
(E) The experiment was performed as in (D) but in the presence of AMP instead
(F and G) Inhibition of wild-type and RIF-resistant E. coli RNAPs by RIF and KglARIF, KglA has a larger binding surface with the RNAP provided
by interactions of the ansa-bridge substituents and areas of
RNAP that have not been previously accessible by rifamycin de-
rivatives. As a result, KglA has an altered binding conformation
compared with RIF, which makes it maintain higher activity
against both RIF-resistant RNAPs and RIF-resistant bacteria.
RESULTS
Isolation of KglA
Actinomycete bacteria have historically been an excellent
source of bioactive compounds, particularly antibiotics. To iden-
tify new antibiotics targeting transcription, we screened a subset
of strains from the Demuris collection of actinomycetes for their
ability to inhibit cell growth and to inhibit cellular transcription. As
a reporter strain, we used a previously describedB. subtilis strain
that has a lacZ gene fused to the promoter of the bacterial
helicase helD. This promoter was selected as the one that is up-
regulated during the stress caused by partial inhibition of tran-
scription in sub-inhibitory concentrations of an antibiotic (Urban
et al., 2007a). In the disk assay shown in Figure 1A, when a paper
disk soaked with antibiotic is placed on the X-gal-infused agar
plate with a lawn of growing cells, this results in a colorimetric
response at the edge of the zone of growth inhibition, observed
as a blue halo (Figure 1A, left; compare the halos produced by
RIF and carbenicillin, an inhibitor of cell wall synthesis). The
isolate Amycolatopsis DEM30355 was of particular interest
because it produced a compound (later identified as KglA, see
below) that gave a blue halo at the edge of the zone of bacterial
growth inhibition, indicative of transcription inhibition (Figure 1A,
left). Importantly, in contrast to RIF, this new compound inhibited
the RIF-resistant B. subtilis strain (bH482R; bH526R in E. coli
numbering) (Figure 1A, right). We cultivated Amycolatopsis
DEM30355 in a stirred tank bioreactor for 103.5 hr and extracted
the secondary metabolites from the supernatant using Amberlite
XAD-16 beads. Subsequent elution with methanol, extraction
with ethyl acetate, and purification bymultistep chromatography
(STAR Methods) produced an orange crystalline compound that
retained the observed biological activity against both the
reporter and RIF-resistant strains (Figure 1A). Electrospray
ionization-mass spectrometry (ESI-MS) revealed the mass,
[M+Na]+ = 1004.3866 m/z (Figure S1A), which corresponded to
the mass of the previously described KglA. 1H and 13C
nuclear magnetic resonance (NMR), extensive 2DNMR analysis,
and, finally, single-crystal X-ray analysis (Figures S1B–S1D;(KglA). Paper disks soaked with antibiotics were placed on the lawns of wild-
artial inhibition of transcription (left), and RIF-resistantB. subtilis (right). Note the
s.
ons in KglA are highlighted. The semisynthetic group of RIF is shown in purple.
ontaining the T7A1 promoter. Runoff, termination, and abortive tri- and tetra-
otides under these electrophoretic conditions.
(pppApUpC) abortive products in the presence of RIF and KglA. Transcription
CpA primer). Note that, in the 33% gel, runoff and termination products remain
of ATP.
. Error bars (F) are ± SD. The brackets (G) contain ± SE and the Hill slope.
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compound to be KglA (Figure 1B).
KglA is an antibiotic originally isolated from the fermentation
broth of Nocardia mediterranei var. kanglensis 1741-64 (Wang
et al., 1988), for which no mode of action has been previously
proposed, and only limited information regarding its biological
activity has been reported. It is an ansamycin antibiotic that
shares similarities with rifamycins, albeit with a number of un-
usual structural features. Most notably, KglA differs from known
rifamycins and their semisynthetic derivatives in that it contains
two large ansa bridge substituents, a pendant 2,2-dimethyl suc-
cinic acid side chain at C20 and a unique sugar moiety (b-O-3,4-
O,O’-methylene digitoxose) at C27 (Figure 1B). Furthermore,
these modifications are unusual for bioactive natural and semi-
synthetic rifamycins, whose modifications are typically concen-
trated at the naphthoquinone core.
Mode of Action and Specificity of KglA
Activation of the helD promoter and its structural similarity to the
rifamycins suggested that KglA targets bacterial RNAP. There-
fore, we analyzed the effects of KglA on in vitro transcription
by wild-type E. coli RNAP. KglA efficiently inhibited transcription
on a linear DNA template containing the strong T7A1 promoter
(Figure 1C). Inhibition of full-sized RNA products (run off or termi-
nated) coincided with increased accumulation of short abortive
tri- and tetra-nucleotide products (Figure 1C; the reactions
were started with the dinucleotide primer CpA). Such a mode
of action is characteristic of the rifamycins (Campbell et al.,
2005; McClure and Cech, 1978), as can be seen from the pattern
of inhibition of transcription by RIF (Figure 1C). In this mode of
action, the antibiotic binds in the pathway of the nascent RNA,
physically blocking its extension and inducing the release of
short RNAs as abortive products.
Dinucleotide primer CpA that was used to start transcription
does not carry a negatively charged triphosphate moiety at the
50 end, which is present in NTPs used by RNAP in vivo. There-
fore, we analyzed the effects of RIF and KglA in a native situa-
tion when transcription was started with ATP (in the absence of
the CpA primer). As can be seen in Figure 1D, KglA completely
blocked the formation of the triphosphorylated trinucleotide,
pppApUpC, whereas RIF allowed some of its production
(compare lanes 4, 5, and 6). Furthermore, KglA strongly dimin-
ished (70-fold inhibition) the formation of the first dinucleotide,
pppApU, whereas RIF had only a moderate effect (3-fold inhibi-
tion) (compare lanes 7, 8, and 9). Next, to start the reaction, we
used AMP, which lacks g and b 50 phosphates, present in ATP
(Figure 1E). KglA only moderately inhibited formation of pApU
(4-fold), suggesting that it is g and, possibly, b phosphates at
the 50 end of the initiating nucleotide that clash with the addi-
tional groups of KglA (compare lanes 7, 8, and 9). However,
the formation of trinucleotide pApUpC was still strongly in-
hibited by KglA compared with RIF (Figure 1E, lanes 4, 5,
and 6). These results further suggest that extra groups and/or
the mode of binding of KglA provide an additional steric and/
or electrostatic (KglA has a negatively charged C20 2,2-
dimethyl succinic acid side chain) hindrance for translocation
of the 50 phosphorylated dinucleotide RNA. Furthermore, KglA
interference with the 50 triphosphate moiety of the initiating4 Molecular Cell 72, 1–12, October 18, 2018nucleotide leads to inhibition even of the first phosphodiester
bond formation (see structural support for these find-
ings below).
The half maximal inhibitory concentration (IC50) values of KglA
and RIF were similar against wild-type RNAP (Figures 1G and
1F). However, despite having a similar mode of action as RIF,
we observed that KglA killed RIF-resistant bacteria (compare
the inhibition zones in Figure 1A, right). To investigate this phe-
nomenon, we prepared E. coli RNAPs carrying a series of RIF-
resistant mutations, including bS531L, bD516V, bD516Y,
bH526Y, bH526P, bH526R, and bI572F. These mutations corre-
spond to the RIF resistance mutations in M. tuberculosis most
frequently observed in clinical isolates, with bS531L, bD516V,
and bH526Y accounting for 73% of all clinical RIF-resistant
M. tuberculosis isolates (Gill and Garcia, 2011). Compared with
RIF, KglA was much more potent against six of seven RIF-resis-
tant RNAPs (Figures 1G and 1F); in particular, KglA was 10 times
more active than RIF against the bS531L and bD516V mutants.
Note that, although mutations at bH526 made RNAP insensitive
to RIF (no inhibition at 2.5 mg/mL), KglA was still able to inhibit
RNAPs with these mutations.
These results and in vivo data (Figure 1A) suggest that KglA
binds to RNAP in the RIF-binding pocket of the b subunit but in
a manner different from known rifamycins, resulting in an
increased resilience to the RIF-resistant amino acid substitutions
in the RIF-binding pocket of RNAP. Furthermore, themode of ac-
tion of KglA deviates from that of RIF because KglA more effi-
ciently inhibits the early stages of RNA synthesis.
Structural Basis of RNAP Inhibition by KglA
To reveal the basis of the KglA efficacy enhancement as induced
by the modifications of the ansa bridge in comparison with
rifamycin, we performed a crystallographic analysis of the com-
plexes of KglA with RNAPs. To analyze the RNAP and KglA inter-
action on the atomic scale, a crystal of the T. thermophilusRNAP
sA holoenzyme-pyrG promoter DNA complex (Murakami et al.,
2017) was used to determine the X-ray crystal structure of the
RNAP-KglA complex at 3.0-A˚ resolution (Table 1). Additionally,
to understand the mechanism of inhibition of RIF-resistant
RNAP by KglA, the crystal of the E. coli bS531L RNAP s70 holo-
enzyme (Molodtsov et al., 2017) was used to determine the
structure of theRNAP-KglA complex at 4.1-A˚ resolution (Table 1).
The electron density maps of both RNAPs show unambiguous
densities for the compound located in the RIF-binding pockets
in the b subunits (Figures 2A and 2B). The binding modes of
KglA to the RNAPs are almost identical; therefore, the atomic
resolution structure of T. thermophilus RNAP-KglA was used
for the precise modeling of KglA in complex with E. coli RNAP.
The binding mode of KglA is similar to that of RIF and involves
the formation of hydrogen bonds with the same amino acid res-
idues of the RIF-binding pocket, including bQ393, bS411, and
bR420 (side chain) and bF394 (main chain) (Figures 2C and
S2A; the numbering is for T. thermophilus; see Figures S2C
and S2D for the corresponding amino acid residues in E. coli
and M. tuberculosis RNAPs). Because of a different topology
of the ansa bridge of KglA (Figure S2B), the C23 hydroxyl group
does not form an additional hydrogen bond with bF394, as
observed in the T. thermophilus RNAP-RIF complex. However,
Table 1. Collection of Crystallographic Data and Refinement
Statistics
Complex Eco RNAP – KglA Tth RNAP – KglA
PDB code 6CUX 6CUU
Data Collection
Space group P212121 C2
Cell dimensions
a (A˚) 188.167 185.221
b (A˚) 204.685 101.315
c (A˚) 311.577 294.279
b () 90 98.886
Resolution (A˚) 50.0–4.1 50.0–3.0
Total reflections 608,898 358,319
Unique reflections 93,684 107,473
Redundancy 6.5 (6.2) 3.3 (3.0)
Completeness (%)a 99.9 (100.0) 99.7 (97.1)
I / sa 16.2 (1.95) 10.2 (1.14)
Rsym (%)
a 7.7 (85.1) 9.6 (61.4)
CC1/2a (0.633) (0.629)
Refinement
Resolution (A˚) 45.03–4.1 46.3–3.0
Rwork 0.2100 0.2012
Rfree 0.2547 0.2483
No. of atoms 54,867 28,254
RMSDs
Bond length (A˚) 0.013 0.006
Bond angles () 1.776 1.089
Clashscore 11.47 5.84
Ramachandran
favored, %
91.57 97.64
Ramachandran
outliers, %
0.94 0.35
RMSD, root-mean-square deviation.
aHighest-resolution shells are shown in parentheses.
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lishes a hydrogen bond with the side chain of bR134 (Figure 2C).
This KglA ansa bridge side chain inserts into a shallow pocket in
the RIF-binding site and establishes additional non-polar inter-
actions with the surrounding residues, significantly increasing
the binding surface of KglA compared with RIF (Figure 2C).
One of the structural consequences of the sugar side chain ac-
commodation in the RIF-binding pocket is a rotational shift of
KglA that increases the distance between the naphthalene
core and the binding surface of the pocket compared with RIF
(Figure 2D).
To validate the new interaction of the C27 b-O-3,4-O,O’-meth-
ylene digitoxose side chain with bR134, we constructed an
E. coli RNAP carrying a mutation at the corresponding amino
acid residue, bR143A. Themutation had little effect on RIF sensi-
tivity (Figure S2E, left). However, KglA was at least an order of
magnitude less effective against bR143A RNAP than against
wild-type RNAP, indicating the importance of this interactionfor KglA binding (Figure S2E, center). The IC50 of KglA for
bR143A RNAP was still lower than for any RIF-resistant mutant
RNAP, indicating that interactions of KglA within the rest of
the RIF-binding pocket were still critical for its binding. Only a
double mutation, bR143A/S531L, led to KglA resistance (Fig-
ure S2E, right).
Thepresenceof additional bulky sidechains on the ansabridge
of KglA has an effect on the mechanism of de novo transcription
initiation. Ansamycin binding in the RIF-binding pocket inhibits
transcription by clashing with the 50 end of a nascent RNA.
Modeling shows that, in the T. thermophilus RNAP-RIF complex,
the triphosphate moiety of the initiating nucleoside triphosphate
(NTP) guidedbyhydrogenbondswith sidechainsof twoessential
residues, bQ567 and bH999 (Basu et al., 2014), moderately
clashes with the C3 side chain of RIF (Figure 2E, right). This clash
does not strongly affect the formation of the first phosphodiester
bond, likely because of flexibility of the C3 side chain. Even in the
presence of RIF, there is an empty space (triphosphate retreat
zone) that allows for accommodation of the 50 triphosphate group
followed by an extension of the nascent RNA to 3-mer (McClure
and Cech, 1978) before a severe clash with the +1 NTP inhibits
further primer extension (Figure 2E, right). In contrast, the posi-
tional shift of KglA and the orientation of the negatively charged
C20 2,2-dimethyl succinic acid side chain not only do not leave
space for accommodation of the 50 triphosphate group but also
interfere with the correct placement of the initiating NTPs (Fig-
ure 2E, left), which explains the strong inhibition of the initial dinu-
cleotide synthesis (Figure 1D). The electrostatic repulsion by the
C20 2,2-dimethyl succinic acid side chain of KglA can also
explain the inhibition of monophosphorylated pApUpC synthesis
(which is allowed by RIF; Figure 1E).
A comparative analysis of the structures of the E. coli bS531L
RNAP s70 holoenzyme in apo form and in complex with RIF and
KglA reveals the mechanism of KglA’s efficiency against many
RIF-resistant forms of mutant RNAPs (Figure 2F). The amino
acid substitution bS531L is the most clinically important RIF-
resistant mutation in bacterial RNAP because of its low structural
and functional effects on the enzyme in the absence of RIF. As
shown in a recent study (Molodtsov et al., 2017), RIF binding to
the mutant RNAP results in a steric clash of the naphthalene
core with the side chain of b531L, which triggers disordering of
a constituent part of the RIF-binding pocket, the fork loop2 (Fig-
ure 2F, left versus right). This partial disordering of the RIF-bind-
ing site efficiently prevents RIF binding. The naphthalene core of
KglA is almost identical to RIF; however, it is rotated in the bind-
ing site compared with RIF (Figure 2D). This positional shift al-
lows KglA to maintain a distance to b531L, avoiding a severe
clash with the residue and minimizing structural rearrangements
of the fork loop2 and the binding pocket (Figure 2F, center). This
fine-tuning of the core binding mode and the increased interac-
tion surface provided by the C27 sugar side chain enable high
affinity of KglA in a broad context of RIF resistance.
Kanglemycin A Has Antimicrobial Activity against
MDR-M. tuberculosis and Other Gram-Positive
Pathogens
The above results suggested that KglA may be effective
against RIF-resistant bacteria, in particular against clinicallyMolecular Cell 72, 1–12, October 18, 2018 5
Figure 2. KglA Binding to Free and Pro-
moter-Bound RNAP Holoenzyme
(A) Overall views of E. coli (left) and T. thermophilus
(right) RNAPs with KglA bound in the RIF-binding
pocket. RNAPs (gray core and orange s) and DNA
(blue) are shown as ribbon models, and KglA (red)
is shown as a stick model.
(B) Electron density maps of KglA in complexes
with T. thermophilus (top) and E. coli (bottom)
RNAPs. Electron densities are shown as a light
bluemesh, and KglA molecules are shown as stick
models colored by element. The ansa bridge side
chains of KglA extending from C20 and C27 are
colored in yellow.
(C) A close-up view of the RIF-binding pocket of
the T. thermophilus RNAP containing KglA (in red,
with the side chains in yellow). RNAP is shown as a
transparent surface model (light blue), KglA is
shown as a stick model with the ansa bridge side
chains labeled, and the b subunit residues forming
the RIF-binding pocket are shown as stickmodels.
The hydrogen bonds between KglA and b amino
acid residues (colored by element) are depicted by
yellow dotted lines; the bR134 involved in polar
interaction with the C20 sugar of KglA is shown
in blue.
(D) A side view of the RIF-binding pocket shown in
(C). KglA is overlaid on RIF (gray); the side chains
of the two molecules are labeled. KglA maintains a
larger distance to the wall in the RIF-binding
pocket than RIF.
(E) Modeling of the initiating nucleotides in the
active site of the T. thermophilus RNAP (from PDB:
4Q4Z) in the presence of KglA (left) and RIF (right).
The ribonucleotides (red), the bQ567 and bH999
residues coordinating the 50 end triphosphate
(blue), and KglA and RIF (gray) are shown as stick
and sphere models. The side chains of the in-
hibitors and the positions of the initiating NTPs are
indicated. Red arrows indicate the translocation
directions for the corresponding substrates.
(F) Structural rearrangements in the RIF-binding
pocket of E. coli bS531L RNAP triggered by KglA
and RIF binding. RNAP is shown as a ribbonmodel
in gray, the structured regions of the fork loop2 are
shown in green, and the b531L residue (blue), KglA
(colored by element with yellow side chains), and
RIF (colored by element) are shown as stick and
sphere models. The side chains of KglA and RIF
are indicated. Arrows mark the clash points be-
tween the naphthalene cores of the corresponding
compounds with the b531L side chain.
See also Figure S2.
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Figure 3. KglA Inhibits Mycobacterial RNAP
and Retains Antimicrobial Activity against
MDR-M. tuberculosis
(A) Dose-dependent growth inhibition of the
RIF-susceptible M. tuberculosis strains H36Rv
(black) and 1192/015 (red) and RIF-resistant
M. tuberculosis 08/00483E (blue) by KglA (solid
line, solid symbols) and RIF (dashed line, open
symbols). Data presented are the mean of four in-
dependent experiments ± SD and analyzed using a
Student’s t test.
(B) MIC values ± SD, as determined using the
modified Gompertz function for M. tuberculosis
strains H37Rv, 1192/015, and 08/00483E, which
were exposed to RIF or KglA.
(C) Mode of action of KglA and RIF against
M. smegmatis RNAP. The experiment was per-
formed exactly as in Figure 1D. Note that the high
radioactive background compared with Figure 1D
is due to much lower activity of M. smegmatis
RNAP.
(D) Inhibition of M. smegmatis RNAP by RIF and
KglA.
Error bars are ± SD. Shown in brackets are the IC50
values ± SE.
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KglA against a clinical MDR-M. tuberculosis isolate (Beijing
08/00483E) that is fully resistant to RIF (Jamieson et al.,
2014; Zhang et al., 2014b) and the other first-line antibiotics
(isoniazid, ethambutol, and pyrazinamide). Beijing 08/00483E
carries the most frequent RNAP amino acid change found
in RIF-resistant M. tuberculosis (bS450L, M. tuberculosis
numbering; bS531L, E. coli numbering; Figures S2C and
S2D). As positive controls, we used the RIF-susceptible refer-
ence strain of M. tuberculosis H37Rv and a RIF-susceptible
clinical isolate, Beijing 1192/015. The clinical strain Beijing
08/00483E was resistant to RIF at 1,024 times the minimum
inhibitory concentration (MIC) for RIF-sensitive strains (Figures
3A and 3B). In contrast, all three strains displayed a dose-
dependent response to KglA exposure (Figure 3A), demon-
strating its antimicrobial activity against MDR-M. tuberculosis.
KglA was statistically significantly more active against RIF-
sensitive Beijing 1192/015 than RIF-resistant Beijing 08/
00483E (Figures 3A and 3B).As seen in Figures 3A and 3B, RIF was
more active against RIF-susceptible
M. tuberculosis cells than KglA. This
apparently contradicted our in vitro results
of very similar inhibition of E. coliwild-type
RNAP by both inhibitors. It is possible that
the mode of inhibition of M. tuberculosis
RNAP by KglA is different from that of
E. coli RNAP. Therefore, we analyzed inhi-
bition of transcription by Mycobacterium
smegmatis RNAP, which is commonly
used as an experimental model for
M. tuberculosis RNAP. Both RNAPs have
an identical amino acid composition ofthe RIF-binding pocket (Figure S2C). We found that RIF and
KglA inhibited RNA synthesis by M. smegmatis RNAP and
E. coli RNAP in a very similar way (compare Figure 1D with Fig-
ure 3C); i.e., KglA fully blocked synthesis of the first dinucleotide
(pppApU), whereas RIF partly allowed synthesis even of the
trinucleotide (pppApUpC). The IC50 of KglA was nearly the
same as that of RIF. Therefore, the affinity of RNAP binding
cannot account for the observed difference in the activities of
RIF and KglA against RIF-sensitive M. tuberculosis cells. The
likely explanation of differences in activities of KglA and RIF
against RIF-sensitive M. tuberculosis is the decreased ability of
KglA to pass through the cell envelope.
We further tested KglA against a range of other species,
including a number of clinically relevant pathogens. These
included 8 Gram-positive bacteria, 10 Gram-negative bacteria,
and 2 eukaryotes (Table 2). Of 10 Gram-negative pathogens,
KglA was active against only Providencia rettgeri. No activity
was observed toward the two strains of eukaryotic microorgan-
isms (yeast):Candida albicans andCandida glabrata. Among theMolecular Cell 72, 1–12, October 18, 2018 7
Table 2. MICs of KglA against Bacterial and Eukaryotic Pathogens
Organism/Isolate Strain Reference KglA (mg/mL) RIF (mg/mL)
Gram-Negative Acinetobacter baumannii ATCC 19606 >128 –
Burkholderia cepacia ATCC 25416 >128 –
Enterobacter cloacae NCTC 11936 >128 –
Escherichia coli NCTC 10418 >128 16a
Klebsiella pneumoniae NCTC 9528 >128 –
Providencia rettgeri NCTC 7475 64 –
Pseudomonas aeruginosa NCTC 10662 >128 –
Salmonella enterica Typhimurium NCTC 74 >128 –
Serratia marcescens NCTC 10211 >128 –
Yersinia enterocolitica NCTC 11176 >128 –
Gram-Positive Bacillus subtilis NCTC 9372 1 –
Enterococcus faecalis NCTC 775 64 –
Enterococcus faecium NCTC 7171 128 –
Listeria monocytogenes NCTC 11994 8 –
Staphylococcus epidermidis NCTC 11047 1 –
Staphylococcus aureus NCTC 6571 0.25 0.004a
Staphylococcus aureus (MRSA) NCTC 11939 1 –
Streptococcus pyogenes NCTC 8306 0.031 –
Yeast Candida albicans ATCC 90028 >128 –
Candida glabrata NCPF 9725 >128 –
S. aureus Bel 97597 2 2
Bel 97598 64 >128
Fin 37481 0.5 %0.008
Fin 54511 32 >128
Fin 54518 128 >128
Fra 462 0.5 %0.008
Fra 920 1 %0.008
Fra 95035 1 0.016
Ger 131/98 (Sger 11d2) 0.5 0.016
Ger 1966/97 (Han 111c) 0.5 %0.008
Ger 2594-1/97 (Sger 11a) 1 0.016
Ger 2594-2/97 (Sger 11b) 0.25 %0.008
EMRSA 15 1729/98 0.5 %0.008
EMRSA 15 1758/98 0.5 %0.008
EMRSA 15 14956 0.5 %0.008
EMRSA 15 12484/98 0.5 %0.008
EMRSA 15 14185/98 0.5 %0.008
EMRSA 15 16822/98 0.5 %0.008
EMRSA 15 19972/98 0.5 %0.008
EMRSA 15 20460/98 0.5 0.016
EMRSA 15 21268/98 0.5 %0.008
EMRSA 15 21698/98 0.5 %0.008
EMRSA 15 2501/98 0.5 %0.008
EMRSA 15 6323/98 0.5 %0.008
EMRSA 16 00036/95 1 0.016
EMRSA 16 00998/95 1 %0.008
EMRSA 16 03732/95 1 0.016
EMRSA 16 07121/95 1 %0.008
(Continued on next page)
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Table 2. Continued
Organism/Isolate Strain Reference KglA (mg/mL) RIF (mg/mL)
EMRSA 16 07924/95 0.5 %0.008
EMRSA 16 18200/95 0.5 %0.008
EMRSA 16 18205/95 0.5 %0.008
EMRSA 16 21354/95 1 0.016
EMRSA 16 23728/98 1 %0.008
EMRSA 16 23729/98 1 %0.008
EMRSA 16 32010/96 1 0.016
EMRSA 16 34256/96 1 %0.008
MRSA NCTC 11939 1 %0.008
Staphylococcus aureus NCTC 6571 0.25 %0.008
aAndrews (2001).
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against staphylococci and Streptococcus pyogenes but less
active against enterococci (MIC, 64–128 mg/mL). The relatively
high activity of KglA against staphylococci prompted evaluation
of its activity against a large collection of methicillin-resistant
Staphylococcus aureus (MRSA) and a comparison of its activity
with RIF. S. aureus NCTC 6571 was re-tested as a control strain
with a known MIC of RIF (EUCAST, 2018). Thirty-seven MRSA
were tested in total, and 33 of these proved to be susceptible
to RIF, as defined by a MIC of % 0.06 mg/mL (EUCAST, 2018).
KglA was substantially less active than RIF against RIF-suscep-
tible MRSA, with MICs of KglA between 0.25 and 1 mg/mL.
Conversely, for 3 of 4 RIF-resistant MRSA, MICs of KglA were
1–3 double dilutions lower than those of RIF, although still rela-
tively high (32–128 mg/mL). In the light of our in vitro data (Figures
1C–1F and 3C), no activity against most of Gram-negative bac-
teria, and lower-than-RIF activity against some Gram-positive
bacteria support the idea of a diminished ability of KglA to enter
bacterial cells. This, however, requires further investigation
coupled with further in vivo analyses to develop KglA as a future
antibiotic.
DISCUSSION
Easily acquired RIF resistance is a major problem in the clinical
usage of rifamycins. The principal finding of our study is that
KglA is much more effective against RIF-resistant RNAPs and
bacteria than its commonly used relative, RIF. The structural
analysis suggests that this is explained by both additional inter-
actions and the binding mode of KglA with RNAP unique to KglA.
The sugar (b-O-3,4-O,O’-methylene digitoxose) and acid (2,2-
dimethyl succinic acid) moieties at C27 and C20 of KglA, respec-
tively, establish these additional contacts and influence the
overall binding mode of KglA in the pocket (Figures 2C and
2D). Compared with RIF, KglA rotates to reposition slightly
away (by 1.2 A˚) from the wall of the binding pocket, which may
decrease the effect of resistance mutations arising in RNAP on
its affinity. Thus, the increased distance between the naphtha-
lene core along with the increased binding surface provided by
the ansa-bridge side chains likely represent the mechanisms
that enable KglA to maintain its inhibitory activity against manyRIF-resistant bacterial RNAPs. As the result of additional interac-
tions by the sugar moiety with the protein, only an unlikely event
of two simultaneous mutations in the RIF-binding pocket can
lead to KglA resistance.
KglA inhibits RNA synthesis at the stage of the first phospho-
diester bond (2-mer RNA) formation, which is different from RIF,
which inhibits formation of the second phosphodiester bond
(3-mer RNA) (Figures 1D and 2E). Our biochemical and structural
data suggest that this may happen because of the steric and/or
electrostatic clash of the C20 2,2-dimethyl succinic acid side
chain of KglA with g and/or b phosphates of the +1 NTP that
may disturb the conformation of initiating nucleotides and,
thus, catalysis. We cannot directly compare these results with
the previous study that found that some rifamycins may inhibit
RNA synthesis one step earlier than RIF (Artsimovitch et al.,
2005) because they used a 50 non-phosphorylated dinucleotide
to start transcription. We, however, did not observe inhibition
of 50 non-phosphorylated trinucleotide synthesis by KglA (Fig-
ure 1C), as observed for some of the rifamycins in that study
(Artsimovitch et al., 2005), suggesting that inhibition of 50 triphos-
phorylated dinucleotide synthesis by KglA takes place via a
different mechanism.
KglA, compared with RIF, appears to show reduced penetra-
tion through the bacterial cell envelope, likely because of the
presence of the polar carboxyl group at C20. For example,
KglA has minimal activity against Gram-negative bacteria in
comparison with RIF and displays higher MICs than RIF against
most of the Gram-positive species tested. However, KglA is
more effective than RIF against RIF-resistant Gram-positive bac-
teria. Notably, it is effective against MDR-M. tuberculosis. KglA
inhibited the growth of MDR-M. tuberculosis (strain 08/00483E
at a MIC of 0.854 mg/mL [850.3 nM]), which was completely
resistant to RIF because of a bS450L substitution (bS531L in
E. coli numbering). Finding new antibiotics for the treatment of
MDR-TB is a challenge, and KglA demonstrates potential as a
candidate for further development, particularly in light of the
fact that the MIC of KglA is lower than the MIC values displayed
for both isoniazid and pyrazinamide against drug-susceptible
M. tuberculosis, and there is a wealth of information about
drug toxicity and patient responses to RIF. These considerations
are likely to accelerate the progression of KglA or its derivativesMolecular Cell 72, 1–12, October 18, 2018 9
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resistant TB.
A new mode of KglA binding to RNAP may enrich the strategy
of structure-guided antibiotic design against RIF-resistant path-
ogens such as MDR-M. tuberculosis. RIF resistance caused by
apointmutation of theb subunit of RNAP is associatedwith either
loss of important contact between a target and a compound (in
the case of bS531L) or steric exclusion of a compound from its
binding site (in the case of bH526Y) (Molodtsov et al., 2017). In
many cases, research efforts focusing on developing new antibi-
otics targeting the RIF-resistant bacterial RNAP are searching for
new interaction surfaces away from the RIF-binding pocket (Lin
et al., 2017; Maffioli et al., 2017). The enhanced affinity of KglA
for certainRIF-resistant RNAPsalongwith themoderate changes
in itsmode of binding comparedwith RIF (Figure 2D) indicate that
theRIF-binding pocket still possesses significant potential for the
development of potent antibiotics against certain RIF-resistant
pathogens. Targeting the RIF-binding pocket has some advan-
tages comparedwith targeting a new site. For example, develop-
ment of resistance to KglA is possible via additional mutations in
the RIF-binding pocket (e.g., bR143A; Figure S2E) in addition to
the first RIF-resistantmutation (e.g., bS531L); however, suchmu-
tations may compromise the transcriptional integrity and further
diminish the fitness of the RNAP, rendering the resulting patho-
gens non-viable (Song et al., 2014). Another important advantage
of developing new rifamycin derivatives is that this approach ex-
ploits thewell-known rifamycin scaffold andmay likely overcome
some obstacles common in the development of new antibiotics,
such as the problems of drug permeability through bacterial
membranes, human toxicity, and specificity (Aristoff et al., 2010).
The modifications in the ansa bridge are highly unusual in
bioactive rifamycins, with even minor semisynthetic modifica-
tions in an ansa bridge often leading to loss of RNAP inhibition
(see Introduction). Our study reveals the significant potential of
increasing the affinity of the rifamycins to RNAP via ansa bridge
modifications, in particular by demonstrating that C27 substitu-
tion can allow access to a previously unexplored hydrophobic
pocket adjacent to the RIF-binding pocket while maintaining
the critical interactions between the rifamycin backbone and
the RIF-binding pocket of RNAP. Furthermore, substitution at
C20 with a flexible carboxylic acid residue has revealed the po-
tential for new drug-initiating NTP interactions in the rifamycins.
Altogether, KglA provides an example of an evolved solution to
RIF resistance in which these unusual ansa bridge modifications
lead to improved potency against RIF-resistant RNAPs and rep-
resents an important starting point for the development of new
therapeutic agents.STAR+METHODS
Detailed methods are provided in the online version of this paper
and include the following:
d KEY RESOURCES TABLE
d CONTACT FOR REAGENT AND RESOURCE SHARING
d METHOD DETAILS10 MoB Disk diffusion assay
B Isolation of KglA from Amycolatopsis sp. DEM30355lecular Cell 72, 1–12, October 18, 2018B Small molecule X-ray crystallography including abso-
lute configuration of KglA
B NMR analysis of KglA
B Purification of E. coli RNAP core enzyme and s70, and
M. smegmatis RNAP holoenzyme for transcription
assays
B In vitro transcription
B Crystallization of RNAP – KglA complexes
B Crystallographic data collection and X-ray crystal
structure determinations
B Determination of minimum inhibitory concentrations
(MICs) for M. tuberculosis
B Determination of minimum inhibitory concentrations
for other bacteria
d DATA AND SOFTWARE AVAILABILITYSUPPLEMENTAL INFORMATION
Supplemental Information includes two figures and two tables and can be
found with this article online at https://doi.org/10.1016/j.molcel.2018.08.028.ACKNOWLEDGMENTS
We thank the staff at the MacCHESS for support with crystallographic data
collection. We also thank UK Engineering and Physical Sciences Research
Council for X-ray crystallography facilities (grant EP/F03637X/1), Dr U.
Baisch (Newcastle University) for measuring the CuKalpha diffraction data,
Diamond Light Source for access to beamline I19 (award MT8682), Prof.
W. McFarlane (Newcastle University) for NMR support, and Dr. J. Gray (New-
castle University) for HRMS analysis. We acknowledge the PHE National
Mycobacterium Reference Laboratory (NMRL) for providing M. tuberculosis
Beijing strains 1192/015 and 08/00483E. This work was supported by Well-
come Trust Investigator Award 102851 and Leverhulme Trust Prize PLP-
2014-229 (to N.Z.), Innovate UK grants 100953 and 131143 (to N.E.E.A.), a
Royal Society University Research Fellowship (to Y.Y.), NIH grant
GM087350 (to K.S.M.), a Department of Health Grant in Aid and The PHE
Pipeline Fund (to J.B.; the views expressed in this publication are those of
the authors and not necessarily those of Public Health England or the
Department of Health), and UK Medical Research Council studentship MR/
N018613/1 (to J.H.).AUTHOR CONTRIBUTIONS
H.M., L.C., J.H., and Y.Y. performed biological experiments and analyzed the
data. B.K., S.M.L., and N.E.E.A. purified KglA. V.M., Y.S., and K.S.M. per-
formed crystallographic experiments and analyzed the structures. M.J.H.,
S.M.L., and C.W. performed the NMR analysis and structural assignment of
KglA. W.C. performed small-molecule X-ray crystallography. C.W.M., R.E.J.,
and J.B. measured the MICs for the M. tuberculosis strains. J.D.P. and
E.C.L.M. measured KglA MICs for other species. J.E., N.E.E.A., and N.Z. con-
ducted the study. J.B., C.W.M., V.M., M.J.H., K.S.M., and N.Z. wrote
the paper.DECLARATION OF INTERESTS
N.E.E.A. is an employee of and J.E. is a scientific founder of and shareholder in
Demuris Ltd. Demuris and Newcastle University have filed UK patent
1812078.2.
Received: May 10, 2018
Revised: July 19, 2018
Accepted: August 17, 2018
Published: September 20, 2018
Please cite this article in press as: Mosaei et al., Mode of Action of Kanglemycin A, an Ansamycin Natural Product that Is Active against Rifampicin-
Resistant Mycobacterium tuberculosis, Molecular Cell (2018), https://doi.org/10.1016/j.molcel.2018.08.028REFERENCES
Adams, P.D., Afonine, P.V., Bunko´czi, G., Chen, V.B., Davis, I.W., Echols, N.,
Headd, J.J., Hung, L.-W., Kapral, G.J., Grosse-Kunstleve, R.W., et al. (2010).
PHENIX: a comprehensive Python-based system for macromolecular struc-
ture solution. Acta. Cryst. D66, 213–221.
Afonine, P.V., Mustyakimov, M., Grosse-Kunstleve, R.W., Moriarty, N.W.,
Langan, P., and Adams, P.D. (2010). Joint X-ray and neutron refinement with
phenix.refine. Acta Crystallogr. D Biol. Crystallogr. 66, 1153–1163.
Andrews, J.M. (2001). Determination of minimum inhibitory concentrations.
J. Antimicrob. Chemother. 48 (Suppl 1 ), 5–16.
Aristoff, P.A., Garcia, G.A., Kirchhoff, P.D., and Showalter, H.D. (2010).
Rifamycins–obstacles and opportunities. Tuberculosis (Edinb.) 90, 94–118.
Artsimovitch, I., Vassylyeva, M.N., Svetlov, D., Svetlov, V., Perederina, A.,
Igarashi, N., Matsugaki, N., Wakatsuki, S., Tahirov, T.H., and Vassylyev,
D.G. (2005). Allosteric modulation of the RNA polymerase catalytic reaction
is an essential component of transcription control by rifamycins. Cell 122,
351–363.
Bacchi, A., Pelizzi, G., Nebuloni, M., and Ferrari, P. (1998). Comprehensive
study on structure-activity relationships of rifamycins: discussion of molecular
and crystal structure and spectroscopic and thermochemical properties of ri-
famycin O. J. Med. Chem. 41, 2319–2332.
Bacchi, A., Carcelli, M., and Pelizzi, G. (2008). Sampling rifamycin conforma-
tional variety by cruising through crystal forms: implications for polymorph
screening and for biological models. New J. Chem. 32, 1725–1735.
Bae, B., Nayak, D., Ray, A., Mustaev, A., Landick, R., and Darst, S.A. (2015).
CBR antimicrobials inhibit RNA polymerase via at least two bridge-helix
cap-mediated effects on nucleotide addition. Proc. Natl. Acad. Sci. USA
112, E4178–E4187.
Basu, R.S., Warner, B.A., Molodtsov, V., Pupov, D., Esyunina, D., Ferna´ndez-
Tornero, C., Kulbachinskiy, A., and Murakami, K.S. (2014). Structural basis of
transcription initiation by bacterial RNA polymerase holoenzyme. J. Biol.
Chem. 289, 24549–24559.
Bauer, A.W., Kirby, W.M., Sherris, J.C., and Turck, M. (1966). Antibiotic sus-
ceptibility testing by a standardized single disk method. Am. J. Clin. Pathol.
45, 493–496.
Campbell, E.A., Korzheva, N., Mustaev, A., Murakami, K., Nair, S., Goldfarb,
A., and Darst, S.A. (2001). Structural mechanism for rifampicin inhibition of
bacterial rna polymerase. Cell 104, 901–912.
Campbell, E.A., Pavlova, O., Zenkin, N., Leon, F., Irschik, H., Jansen, R.,
Severinov, K., and Darst, S.A. (2005). Structural, functional, and genetic anal-
ysis of sorangicin inhibition of bacterial RNA polymerase. EMBO J. 24,
674–682.
Degen, D., Feng, Y., Zhang, Y., Ebright, K.Y., Ebright, Y.W., Gigliotti, M.,
Vahedian-Movahed, H., Mandal, S., Talaue, M., Connell, N., et al. (2014).
Transcription inhibition by the depsipeptide antibiotic salinamide A. eLife 3,
e02451.
Emsley, P., and Cowtan, K. (2004). Coot: model-building tools for molecular
graphics. Acta Crystallogr. D Biol. Crystallogr. 60, 2126–2132.
EUCAST (2018). European Committee on Antimicrobial Susceptibility Testing.
http://www.eucast.org/clinical_breakpoints/.
Floss, H.G., and Yu, T.W. (2005). Rifamycin-mode of action, resistance, and
biosynthesis. Chem. Rev. 105, 621–632.
Gill, S.K., and Garcia, G.A. (2011). Rifamycin inhibition of WT and Rif-resistant
Mycobacterium tuberculosis and Escherichia coli RNA polymerases in vitro.
Tuberculosis (Edinb.) 91, 361–369.
Gold, B., Roberts, J., Ling, Y., Lopez Quezada, L., Glasheen, J., Ballinger, E.,
Somersan-Karakaya, S., Warrier, T., and Nathan, C. (2016). Visualization of the
Charcoal Agar Resazurin Assay for Semi-quantitative, Medium-throughput
Enumeration of Mycobacteria. J. Vis. Exp. 118, 54690.
Ho, M.X., Hudson, B.P., Das, K., Arnold, E., and Ebright, R.H. (2009).
Structures of RNA polymerase-antibiotic complexes. Curr. Opin. Struct. Biol.
19, 715–723.James, B.W., Williams, A., and Marsh, P.D. (2000). The physiology and path-
ogenicity of Mycobacterium tuberculosis grown under controlled conditions
in a defined medium. J. Appl. Microbiol. 88, 669–677.
Jamieson, F.B., Guthrie, J.L., Neemuchwala, A., Lastovetska, O., Melano,
R.G., andMehaffy, C. (2014). Profiling of rpoBmutations andMICs for rifampin
and rifabutin inMycobacterium tuberculosis. J. Clin. Microbiol. 52, 2157–2162.
Julius, C., and Yuzenkova, Y. (2017). Bacterial RNA polymerase caps RNAwith
various cofactors and cell wall precursors. Nucleic Acids Res. 45, 8282–8290.
Kashlev, M., Nudler, E., Severinov, K., Borukhov, S., Komissarova, N., and
Goldfarb, A. (1996). Histidine-tagged RNA polymerase of Escherichia coli
and transcription in solid phase. Methods Enzymol. 274, 326–334.
Kepplinger, B., Morton-Laing, S., Seistrup, K.H., Marrs, E.C.L., Hopkins, A.P.,
Perry, J.D., Strahl, H., Hall, M.J., Errington, J., and Allenby, N.E.E. (2018).
Mode of Action and Heterologous Expression of the Natural Product
Antibiotic Vancoresmycin. ACS Chem. Biol. 13, 207–214.
Lambert, R.J., and Pearson, J. (2000). Susceptibility testing: accurate and
reproducible minimum inhibitory concentration (MIC) and non-inhibitory con-
centration (NIC) values. J. Appl. Microbiol. 88, 784–790.
Lancini, G., and Zanichelli, W. (1977). Structure-activity relationship in rifamy-
cins, Structure-activity relationships among the semisynthetic antibiotics edn
(New York: Academic Press).
Lin, W., Mandal, S., Degen, D., Liu, Y., Ebright, Y.W., Li, S., Feng, Y., Zhang, Y.,
Mandal, S., Jiang, Y., et al. (2017). Structural Basis of Mycobacterium tubercu-
losis Transcription and Transcription Inhibition. Mol. Cell 66, 169–179.e8.
Maffioli, S.I., Zhang, Y., Degen, D., Carzaniga, T., Del Gatto, G., Serina, S.,
Monciardini, P., Mazzetti, C., Guglierame, P., Candiani, G., et al. (2017).
Antibacterial Nucleoside-Analog Inhibitor of Bacterial RNA Polymerase. Cell
169, 1240–1248.e23.
McClure, W.R., and Cech, C.L. (1978). On the mechanism of rifampicin inhibi-
tion of RNA synthesis. J. Biol. Chem. 253, 8949–8956.
Molodtsov, V., Fleming, P.R., Eyermann, C.J., Ferguson, A.D., Foulk, M.A.,
McKinney, D.C., Masse, C.E., Buurman, E.T., and Murakami, K.S. (2015).
X-ray crystal structures of Escherichia coli RNA polymerase with switch region
binding inhibitors enable rational design of squaramides with an improved
fraction unbound to human plasma protein. J. Med. Chem. 58, 3156–3171.
Molodtsov, V., Scharf, N.T., Stefan, M.A., Garcia, G.A., and Murakami, K.S.
(2017). Structural basis for rifamycin resistance of bacterial RNA polymerase
by the three most clinically important RpoB mutations found in Mycobacterium
tuberculosis. Mol. Microbiol. 103, 1034–1045.
Mukherjee, R., and Chatterji, D. (2008). Stationary phase induced alterations in
mycobacterial RNA polymerase assembly: A cue to its phenotypic resistance
towards rifampicin. Biochem. Biophys. Res. Commun. 369, 899–904.
Mukhopadhyay, J., Das, K., Ismail, S., Koppstein, D., Jang, M., Hudson, B.,
Sarafianos, S., Tuske, S., Patel, J., Jansen, R., et al. (2008). The RNA polymer-
ase ‘‘switch region’’ is a target for inhibitors. Cell 135, 295–307.
Murakami, K.S. (2013). X-ray crystal structure of Escherichia coli RNA poly-
merase s70 holoenzyme. J. Biol. Chem. 288, 9126–9134.
Murakami, K.S., Shin, Y., Turnbough, C.L., Jr., and Molodtsov, V. (2017). X-ray
crystal structure of a reiterative transcription complex reveals an atypical RNA
extension pathway. Proc. Natl. Acad. Sci. USA 114, 8211–8216.
Nateche, F., Martin, A., Baraka, S., Palomino, J.C., Khaled, S., and Portaels, F.
(2006). Application of the resazurin microtitre assay for detection of multidrug
resistance in Mycobacterium tuberculosis in Algiers. J. Med. Microbiol. 55,
857–860.
Otwinowski, Z., and Minor, W. (1997). [20] Processing of X-ray diffraction data
collected in oscillation mode. Methods Enzymol. 276, 307–326.
Perlman, D. (1977). Structure-activity relationships among the semisynthetic
antibiotics (New York: Academic Press).
Roghanian, M., Zenkin, N., and Yuzenkova, Y. (2015). Bacterial global regula-
tors DksA/ppGpp increase fidelity of transcription. Nucleic Acids Res. 43,
1529–1536.Molecular Cell 72, 1–12, October 18, 2018 11
Please cite this article in press as: Mosaei et al., Mode of Action of Kanglemycin A, an Ansamycin Natural Product that Is Active against Rifampicin-
Resistant Mycobacterium tuberculosis, Molecular Cell (2018), https://doi.org/10.1016/j.molcel.2018.08.028Ryu, Y.J., Koh, W.J., and Daley, C.L. (2016). Diagnosis and Treatment of
Nontuberculous Mycobacterial Lung Disease: Clinicians’ Perspectives.
Tuberc. Respir. Dis. (Seoul) 79, 74–84.
Sandgren, A., Strong, M., Muthukrishnan, P., Weiner, B.K., Church, G.M., and
Murray, M.B. (2009). Tuberculosis drug resistance mutation database. PLoS
Med. 6, e2.
Smith, A.J., and Savery, N.J. (2005). RNA polymerase mutants defective in the
initiation of transcription-coupled DNA repair. Nucleic Acids Res. 33, 755–764.
Song, T., Park, Y., Shamputa, I.C., Seo, S., Lee, S.Y., Jeon, H.S., Choi, H., Lee,
M., Glynne, R.J., Barnes, S.W., et al. (2014). Fitness costs of rifampicin resis-
tance in Mycobacterium tuberculosis are amplified under conditions of
nutrient starvation and compensated by mutation in the b0 subunit of RNA po-
lymerase. Mol. Microbiol. 91, 1106–1119.
Tupin, A., Gualtieri, M., Leonetti, J.P., andBrodolin, K. (2010). The transcription
inhibitor lipiarmycin blocks DNA fitting into the RNA polymerase catalytic site.
EMBO J. 29, 2527–2537.
Urban, A., Eckermann, S., Fast, B., Metzger, S., Gehling, M., Ziegelbauer, K.,
R€ubsamen-Waigmann, H., and Freiberg, C. (2007a). Novel whole-cell anti-12 Molecular Cell 72, 1–12, October 18, 2018biotic biosensors for compound discovery. Appl. Environ. Microbiol. 73,
6436–6443.
Wang, N.J., Fu, Y., Yan, G.H., Bao, G.H., Xu, C.F., and He, C.H. (1988).
Isolation and structure of a new ansamycin antibiotic kanglemycin A from a
Nocardia. J. Antibiot. (Tokyo) 41, 264–267.
World Health Organization (2017). Global tuberculosis report. CC BY-NC- SA
3.0 IGO.
Zenkin, N., Kulbachinskiy, A., Yuzenkova, Y., Mustaev, A., Bass, I., Severinov,
K., and Brodolin, K. (2007). Region 1.2 of the RNA polymerase sigma subunit
controls recognition of the -10 promoter element. EMBO J. 26, 955–964.
Zhang, Y., Degen, D., Ho,M.X., Sineva, E., Ebright, K.Y., Ebright, Y.W.,Mekler,
V., Vahedian-Movahed, H., Feng, Y., Yin, R., et al. (2014a). GE23077 binds to
the RNA polymerase ‘i’ and ‘i+1’ sites and prevents the binding of initiating nu-
cleotides. eLife 3, e02450.
Zhang, Z., Dai, F., Luo, F., Zhong, M., Huang, Z., Hou, T., and Xu, J. (2014b).
Could high-concentration rifampicin kill rifampicin-resistant M. tuberculosis?
Rifampicin MIC test in rifampicin-resistant isolates from patients with osteoar-
ticular tuberculosis. J. Orthop. Surg. Res. 9, 124.
Please cite this article in press as: Mosaei et al., Mode of Action of Kanglemycin A, an Ansamycin Natural Product that Is Active against Rifampicin-
Resistant Mycobacterium tuberculosis, Molecular Cell (2018), https://doi.org/10.1016/j.molcel.2018.08.028STAR+METHODSKEY RESOURCES TABLEREAGENT or RESOURCE SOURCE IDENTIFIER
Bacterial and Virus Strains
E. coli BL21(DE3) Novagen Cat# 69450
M. smegmatis mc2155 (SM07) Mukherjee and Chatterji, 2008 N/A
Mycobacterium tuberculosis H37Rv, Beijing 1192/015
and Beijing 08/00483E
PHE National Mycobacterial Reference
Laboratory
N/A
E. coli T7 Express New England BioLabs Cat# C2566H
B. subtilis 168 amyE::PhelD-lacZ cat Urban et al., 2007a N/A
B. subtilis 168 amyE::PhelD-lacZ cat rpoBH482R This paper N/A
Enterobacter cloacae NCTC NCTC 11936
Escherichia coli NCTC NCTC 10418
Klebsiella pneumoniae NCTC NCTC 9528
Providencia rettgeri NCTC NCTC 7475
Pseudomonas aeruginosa NCTC NCTC 10662
Salmonella typhimurium NCTC NCTC 74
Serratia marcescens NCTC NCTC 10211
Yersinia enterocolitica NCTC NCTC 11176
Bacillus subtilis NCTC NCTC 9372
Enterococcus faecalis NCTC NCTC 775
Enterococcus faecium NCTC NCTC 7171
Listeria monocytogenes NCTC NCTC 11994
Staphylococcus epidermidis NCTC NCTC 11047
Staphylococcus aureus NCTC NCTC 6571
Staphylococcus aureus (MRSA) NCTC NCTC 11939
Streptococcus pyogenes NCTC NCTC 8306
Candida glabrata NCPF NCPF 9725
Acinetobacter baumannii ATCC ATCC 19606
Burkholderia cepacia ATCC ATCC 25416
Candida albicans ATCC ATCC 90028
Clinical isolates of methicillin-resistant Staphylococcus
aureus (MRSA) X 36.
Public Heath England, Colindale, UK N/A
T. thermophilus HB8 ATCC ATCC 27634
Chemicals, Peptides, and Recombinant Proteins
Ni-NTA agarose QIAGEN Cat# 30230
HiTrap Q HP, 1 mL GE Healthcare Life Sciences Cat# 29051325
HiLoad 26/600 Superdex 200 GE Healthcare Life Sciences Cat# 28989336
HiTrap Heparin HP, 5 mL GE Healthcare Life Sciences Cat# 17040601
HisTrap HP, 5 mL GE Healthcare Life Sciences Cat# 17524801
Bio-Rex 70 cation exchange resin Bio-Rad Cat# 1425842
Biotage SNAP Ultra 100 g Biotage Cat# FSUL-0442-0100
[alpha-P32]Uridine 50-triphosphate (UTP) Hartmann Analytic Cat# SRP-810
rNTP Set, 100 mM Solutions (ATP, CTP, GTP, UTP) GE Healthcare Cat# 27202501
QuikChange II kit (Stratagene) Agilent Cat# 200523
CpA IBA Lifesciences Cat# 5-0710-186
RIF Sigma Cat# R3501
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REAGENT or RESOURCE SOURCE IDENTIFIER
Resazurin sodium salt Sigma Cat# R7017
CMM MOD2 James et al., 2000 N/A
Middlebrook 7H9 medium BD Difco Cat# 271310
Phosphate buffered saline, pH 7.4 Severn Biotech Cat# 20-74-10
IsoSensitest agar Oxoid Cat# CM0471
Amberlite XAD-16 Sigma Cat# XAD16
Deposited Data
KglA X-ray diffraction data This paper CCDC: 1827601 and 1827602
E. coli RNAP – KglA complex This paper PDB: 6CUX
T. thermophilus RNAP – KglA complex This paper PDB: 6CUU
E. coli RNAP Murakami 2013 PDB: 4YG2
T. thermophilus RNAP – pyrG promoter complex Murakami et al., 2017 PDB: 5VOI
Oligonucleotides
See Table S2 for list of oligonucleotides
Recombinant DNA
pVS10(S531L) Gill and Garcia, 2011 N/A
pGEMD Murakami, 2013 N/A
pET21a-SigA Basu et al., 2014 N/A
pETLrpoB Smith and Savery, 2005 N/A
Software and Algorithms
COOT Emsley and Cowtan, 2004 https://www2.mrc-lmb.cam.ac.uk/
personal/pemsley/coot/
HKL2000 Otwinowski and Minor, 1997 http://www.hkl-xray.com
PHENIX Adams et al., 2010 https://www.phenix-online.org
Pymol PyMOL https://pymol.org/2/
Graphpad 7.00 Prism https://www.graphpad.com/
SigmaPlot 11.0 Systat Software https://systatsoftware.com/
Other
VDX48 Plate with sealant Hampton Research Cat# HR3-275
12 mm x 0.22 mm Siliconized circle cover slides Hampton Research Cat# HR3-279
18 mm Mounted CryoLoop - 20 micron Hampton Research Cat# HR4-973
CrystalCap ALS with vial Hampton Research Cat# HR4-779
Vivaspin sample concentrator (MWCO 10 kDa) GE Healthcare Life Sciences Cat# 28-9323-60
Tecan Sunrise microplate absorbance reader Tecan instruments https://www.tecan.com/
Infinite M1000 multimode plate reader Tecan instruments https://www.tecan.com/
Isolaera ONE Biotage Cat# ISO-1SW
Jeol Lambda 500 MHz spectrometer JEOL Ltd N/A
Jeol ECS 400 MHz spectrometer JEOL Ltd N/A
Gemini X-ray Diffractometer/Atlas detector Oxford Diffraction N/A
Beam Station I19 National Synchrotron Facility
Diamond Light Source
N/A
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Disk diffusion assay
Standard disc diffusion assay (Kirby-Bauer) was performed with the B. subtilis 168 amyE::PhelD-lacZ cat reporter strain or RIF-resis-
tant B. subtilis 168 rpoBH482R strain as described (Bauer et al., 1966). Briefly, disks were loaded with to 10 mg of each drug, air-dried
and placed on nutrient agar plates with embedded lawn of bacteria and x-gal (100 mg/mL). Plates were incubated overnight at 37C
and scanned.
Isolation of KglA from Amycolatopsis sp. DEM30355
The fermentation of the Amycolatiopsis sp. DEM303555 was conducted as previously described. (Kepplinger et al., 2018). One ki-
logram of Amberlite XAD-16 resin was washed with deionized water and then applied to 50 L of filtered culture supernatant in batch
absorption. The material was eluted with 32 L of 100%methanol and concentrated under reduced pressure (2.5 L). The concentrate
was adjusted to pH 6.5 and extracted eight times with an equal amount of ethyl acetate. The organic extracts were combined and
evaporated to dryness to yield 22.5 g of crude extract. A sample of the crude extract (3.91 g) was subjected to silica gel chromatog-
raphy (eluent = 100% ethyl acetate, Biotage SNAP 100 g cartridge). KglA-containing fractions were combined and the solvent was
removed under reduced pressure to give 1.24 g of a dark colored solid. This material was subjected to a second silica gel chroma-
tography step (eluent = linear gradient from diethyl ether to ethyl acetate. Evaporation of the KglA containing fractions yielded
806.2 mg as an orange solid.
Small molecule X-ray crystallography including absolute configuration of KglA
Slow evaporation of a methanol solution of KglA gave crystals suitable for single-crystal X-ray analysis. The molecular structure of
KglA was obtained to high precision using synchrotron radiation with a very small crystal of themethanol solvate at 120 K; all H atoms
were located and freely refined. The short X-ray wavelength of 0.6889 Angstroms did not permit the determination of the absolute
configuration, which was subsequently established unambiguously with CuKalpha radiation and a larger crystal, giving a molecular
structure with otherwise slightly lower precision. CCDC 1827601 and 1827602 contain the supplementary crystallographic data
for this paper, these data can be obtained free of charge from The Cambridge Crystallographic Data Centre (https://www.ccdc.
cam.ac.uk/).
NMR analysis of KglA
All NMR spectra were recorded in CDCl3 at 10
C. 1H and 13C{1H} NMR spectra were recorded directly with a Jeol Lambda 500 MHz
spectrometer (Figure S1), while 1H COSY; 45, 90 and 135 DEPT; HMQC and HMBC were recorded with a Jeol ECS 400 MHz spec-
trometer (not shown). Proton and carbon assignment was performed de novo from both 1D and 2D NMR experiments and was in
close agreement with the literature (Wang et al., 1988, Table S1).
Purification of E. coli RNAP core enzyme and s70, and M. smegmatis RNAP holoenzyme for transcription assays
RIF-resistant mutations were introduced in pETLRpoB plasmid (6xHis-tag on N terminus of b subunit of E. coli RNAP) (Smith and
Savery, 2005) by site-directed mutagenesis using QuikChange II kit (Stratagene). Wild-type or mutant plasmids were transformed
along with pACYCDuet-1_Ec_rpoZ (encoding for u subunit) in T7 Express strain (New England Biolabs). Expression and purification
of core RNAP was performed as described (Kashlev et al., 1996) (with heparin chromatography used instead of gel filtration as sug-
gested). N-terminal 6xHis-tagged E. coli s70 subunit was purified as described (Zenkin et al., 2007).
Cellular M. smegmatis RNAP holoenzyme with 6xHis-tag on C terminus of b’ subunit was purified as E. coli RNAP above from
M. smegmatismc2155 (SM07) (Mukherjee andChatterji, 2008), with exception that cells were grown inMB-7H9media supplemented
with 0.05 Tween 80 and 2% glucose to late exponential phase.
In vitro transcription
One pmol of wild-type or mutant E. coli RNAP core and 3 pmols of s70 (or one pmol ofM. smegmatis holoenzyme) and 0.1 pmols of
linear template containing T7A1 promoter (Julius and Yuzenkova, 2017; Roghanian et al., 2015) were mixed in 7 mL of transcription
buffer (20 mM Tris HCl pH 7.9, 40 mM KCl, 10 mM MgCl2). 1 mL of DMSO containing or not containing antibiotics (concentrations
specified in Figures) was added to the reaction. Transcription was initiated by the addition of 2 mL of the mixture of nucleotides in
transcription buffer, containing (final concentrations): 25 mM CpA or 0.5 mM ATP or 5 mM AMP with different combinations or all
of 100 mM ATP, CTP and GTP and 10 mM a-[32P]UTP (20 Ci/mmol) (Hartmann Analytic). Reactions were stopped after 10-min incu-
bation at 37C by the addition of formamide-containing loading buffer. Products were separated on 20% or 33% denaturing
(8M urea) polyacrylamide gels, revealed by PhosphorImaging (GE Healthcare), and analyzed using ImageQuant software (GE Health-
care). Activities (a sum of run off and termination products) were normalized to the activity without antibiotic, which was taken as
100%. The average activity of at least three replicates for each concentration of antibiotic was plotted (with their standard deviations
as error bars) against concentration and fitted in four parameter logistic equation by nonlinear regression using SigmaPlot. The av-
erages and standard deviations of the three individual IC50s are reported in Figure 1E.Molecular Cell 72, 1–12.e1–e5, October 18, 2018 e3
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The bS531L RIF-resistant mutant E. coli RNAP s70 holoenzyme was prepared and crystallized as previously described (Molodtsov
et al., 2017). The complex of the T. thermophilus RNAP sA holoenzyme bound to pyrG promoter was prepared and crystallized as
previously described (Murakami et al., 2017). To prepare complexes of RNAPs with KglA, the RNAP crystals were soaked overnight
at 22C in the respective cryoprotection solutions supplemented with 1 mMKglA. After the soaking, crystals were frozen by plunging
to liquid N2.
Crystallographic data collection and X-ray crystal structure determinations
The X-ray diffraction datasets were collected at the Macromolecular Diffraction at the Cornell High Energy Synchrotron Source
(MacCHESS) F1 beamline (Cornell University, Ithaca, NY) and the data were processed by HKL2000 (Otwinowski and Minor,
1997). Structures were determined by molecular replacement using the structures of the E. coli RNAP (Murakami, 2013) and the
T. thermophilus RNAP – pyrG promoter complexes (Murakami et al., 2017) as corresponding initial search models. The structures
were refined as the rigid body and the positional refinement with non-crystallographic symmetry and reference model structure re-
straints using the suite of programs Phenix (Afonine et al., 2010). The resulting electron density maps revealed clear maps corre-
sponding to KglA that was not present in the initial search models, and the KglA model was fitted into the density maps using
Coot (Emsley and Cowtan, 2004). The Table 1 contains data collection and refinement statistics for the structures of the determined
RNAP – KglA complexes. The final coordinates and structure factors were deposited to the PDB with ID codes listed in Table 1.
Determination of minimum inhibitory concentrations (MICs) for M. tuberculosis
Bacterial strains and reagents
Mycobacterium tuberculosis strains: H37Rv, Beijing 1192/015 and Beijing 08/00483E (multi-drug resistant, MDR) were used in the
modified resazurin microtiter assay (REMA) plate method. Beijing strains 1192/015 and 08/00483E were obtained from the PHE Na-
tional Mycobacterial Reference Laboratory. Beijing 08/00483E contains a single nucleotide polymorphism (SNP) at position 761155
of C/T, which has resulted in an amino acid change, S450L (corresponding to S531L with E. coli numbering), within the RIF-binding
pocket. Beijing 08/00483E is also resistant to isoniazid, ethambutol, and pyrazinamide, through mutations in known resistance
genes. Other reagents used were: Middlebrook 7H9 medium (BD Difco), OADC supplemented with 0.5% glycerol (24388.295,
VWR Chemicals) and 0.2% Tween 80 (P1754, Sigma), CAMR Mycobacterium Medium MOD2 (CMM MOD2) (James et al., 2000),
RIF (PanReac AppliChem, cat no.A2220) and 0.02% resazurin solution (10 mg resazurin sodium salt (R7017, Sigma) in 50 mL phos-
phate buffered saline, pH 7.4 (Severn Biotech) containing 5% Tween 80) (Gold et al., 2016). All the antibiotics were dissolved in meth-
anol (322415, Sigma) to a stock concentration of 10 mg/mL.
Preparation of bacterial inocula
Bacterial strains were grown in 50 mL of OADC-supplemented, Middlebrook 7H9 medium with 0.5% glycerol and 0.2% Tween 80 in
vented Erlenmeyer flasks, shaken at 37C for 5 days. Inocula for the REMA method were prepared to an OD540 of 0.5, from Middle-
brook 7H9 cultures by diluting cells in CMM MOD2 medium.
Modified resazurin microtiter assay (REMA) plate method
Amodification of the REMAplatemethod previously described by (Nateche et al., 2006) was used. A 10mg/mL stock solution of KglA
was prepared in methanol (322415, Sigma). A two-fold serial dilution of the stock solution was performed in CMM MOD2 medium.
100 ml of each KglA concentration was added to six replicate wells in a 96-well untreated flat bottomed 96-well plate (734-1554,
VWR). Three of the wells remained as ‘‘drug-only’’ wells and the other three wells were ‘‘test wells,’’ which were used to test the ac-
tivity of KglA. 10 ml of bacterial culture was added to the test wells to give a final OD540 of 0.05. Three further wells contained 100 ml of
growth medium and 10 ml of bacterial cells as ‘‘zero-drug’’ controls to confirm exponential growth of the bacteria in the absence of
antibiotic. The drug-only controls allowed for confirmation that there was an absence of colorimetric interference from the candidate
antibiotic. Bacterial cell samples were diluted to an optical density (OD540) of 0.5 and 10 ml of the inoculum was added to each of the
test wells and the zero drug controls. 10 ml of CMMMOD2 growthmediumwas added to the drug-only wells. The 96-well plates were
incubated for 7 days at 37Cwhile shaking at 200 rpm. Drug activity was ascertained by adding 11 ml resazurin to every well of the 96
well-plate and incubating the plate at room temperature for 6 hours. The optical density (OD570) was measured for each well. The
OD570 measurements were converted to a percentage of the zero-drug control so that data were expressed as a percentage of
the growth without antibiotic.
Statistical analyses
TheaverageOD570 for eachdrugconcentrationwasfitted toa sigmoidal curveusing themodifiedGompertz function (y=A+Ce
-eB(x - M))
and theminimum inhibitory concentration (MIC)was identified from thepoint of inflexion of the lower asymptote (Lambert andPearson,
2000). Thiswas applied to themeanof theOD570 of four biological repeats to produce a graphical representation for eachcondition. An
unpaired, two tailed, Students t test was used to determine significance between biological repeats.
Determination of minimum inhibitory concentrations for other bacteria
MICs were determined using the agar dilution method specified by the British Society for Antimicrobial Chemotherapy against a
collection of 56 isolates (Andrews, 2001). Briefly, KglA was initially dissolved in a minimal volume of dimethyl sulfoxide and diluted
in water before incorporation into IsoSensitest agar (Oxoid) at a final concentration range of 128 – 0.031 mg/mL. A final inoculume4 Molecular Cell 72, 1–12.e1–e5, October 18, 2018
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the lowest concentration of KglA that achieved complete inhibition of visible growth. Inhibitor-free controls were also tested,
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The collection included 16 isolates acquired from the National Collection of Type Cultures (NCTC; Colindale, UK), 3 isolates from
the American Type Culture Collection (ATCC; Manassas, USA), and one from the National Collection of Pathogenic Fungi (NCPF;
Colindale, UK). Also included were 36 strains of methicillin-resistant Staphylococcus aureus (MRSA) kindly supplied by Public Health
England (Colindale, UK). These 36 strains were isolated from clinical samples in five European countries and included representatives
of the major clones responsible for outbreaks of infection.
DATA AND SOFTWARE AVAILABILITY
The atomic coordinates and structure factors have been deposited in the Protein Data Bank, https://www.pdb.org (PDB ID codes
6CUX and 6CUU). CCDC 1827601 and 1827602 contain the supplementary crystallographic data for this paper, these data can
be obtained free of charge from The Cambridge Crystallographic Data Centre (https://www.ccdc.cam.ac.uk/).Molecular Cell 72, 1–12.e1–e5, October 18, 2018 e5
